Transforming mental health
Our lead drug candidate is a fixed dose combination of an SSRI and a micro-dose of ibogaine - psychoactive stimulant
Next Generation Therapeutics
for Mental Health Disorders
Harnessing Neuronal Plasticity of Psychedelics
to Overcome Standard of Care Pitfalls
to Overcome Standard of Care Pitfalls
Our goal is to become a leader in the field of psychedelic-combination therapeutics
Once daily oral dosage form
No supervision
No psychoactive effects
No interruption to daily lifestyle
Unleashing the therapeutic
potential of Ibogaine
IBOGAINE
Ibogaine is a psychoactive compound originally isolated from the root bark of the iboga tree (Tabernanthe iboga) in central and west Africa.
It was sold in Franc as a stimulant drug up to the 1970’s under the name Lambarène
It is currently being developed in the US as an anti-addiction drug
Management
Itay is an entrepreneur with vast experience in the private and public sectors. He oversaw the first IPO of medical Cannabis company in the Tel Aviv Stock Exchange. Prior to PsyRx Itay served as the CEO of Hi-Pharma Ltd, a medical cannabis company for 2 years and 7 years as COO of Palgi Sharon - Israeli Municipal Water Corporation.
